Dr. Melanie R. Goldfarb, MD

Dr. Goldfarb practices at Providence Saint John's Health Center in Santa Monica, California, part of Providence Health & Services.

Dr. Goldfarb's NPI, 1306092564, was assigned on August 7, 2008. Dr. Goldfarb graduated from University of Illinois College of Medicine - Chicago in 2005. Dr. Goldfarb holds California license A117052.

Dr. Goldfarb's primary practice is Providence Saint John's Health Center, at 2121 Santa Monica Blvd, Santa Monica, CA 90404 in Los Angeles County. The practice phone is (310) 829-5511.

Dr. Goldfarb's primary practice is Providence Saint John's Health Center in Santa Monica, California, part of Providence Health & Services. Dr. Goldfarb is also affiliated with Cedars-Sinai Medical Center. The medical group on file is Saint John's Physician Partners.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Goldfarb practices, 2 sites in all. Vendor and product names are available with a free account.

Surgery is Dr. Goldfarb's primary specialty in the NPI Registry, under taxonomy code 208600000X. Dr. Goldfarb is board certified in surgery by the American Board of Surgery. Dmand AI has Dr. Goldfarb's licenses on file in 2 states: California and Florida.

CMS data shows 710 Medicare services from Dr. Goldfarb across 10 procedure codes in 2024, for 255 Medicare patients. Medicare paid $63,509 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 255 Medicare patients who saw Dr. Goldfarb in 2024. The largest group is 65 to 74, with 144 patients. 75% of them have high cholesterol, and 60% have high blood pressure. 8% are also on Medicaid. Their average risk score is 1.01, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Goldfarb's median patient age at 69, with 80% women.

In 2024, Dr. Goldfarb wrote 33 Medicare Part D claims for 27 patients. 85% of them were for generic drugs. CMS names the drug for 16 of them, across 1 drug with 11 or more claims each, at $17 in total drug cost. In 2023, CMS named 24 claims across 2 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 90 out of 100 for Dr. Goldfarb for performance year 2024, reported as part of a group. Dr. Goldfarb accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Goldfarb as offering telehealth.

Dmand AI links 121 papers to Dr. Goldfarb, published from 2009 to 2025. 2017 was the busiest year, with 14. The most frequent topics are Thyroid Neoplasms, Thyroidectomy and Adenocarcinoma. Dr. Goldfarb has published most often in Ann Surg Oncol. Dr. Goldfarb's most frequent co-authors are John J. Doski, MD, Jed G. Nuchtern, MD and Trevan Dale Fischer, MD.

CMS Open Payments shows 67 general payments to Dr. Goldfarb from 27 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 78% of the total. Sanofi and Genzyme US Companies paid the most, $38,150.

Dmand AI lists 3 awards for Dr. Goldfarb, most recently Young Investigator Award in 2013.

Dr. Goldfarb graduated from University of Illinois College of Medicine - Chicago in 2005. Dr. Goldfarb is a member of AACE, American Association of Endocrine Surgeons, ACS, ASCO, ATA and Childrens Oncology Group.

Dr. Goldfarb is in network with 14 carriers, including Elevance, Blue Cross Blue Shield of Michigan and United Healthcare. PPO plans come from the most carriers, 9. Check the plan with the practice before a visit.